Indian Shares Seen Higher At Open As Global Bond Selloff Slows

U.S. Treasury debt buyback plans to cover 10–30 year maturities are supporting bond-market stability as Indian equities look set to open higher, while Brent remains elevated near $92/bbl (+3% this week) amid renewed U.S. economic pressure on Iran. The rupee weakened to 95.76 per dollar (weakest since late July) on geopolitical tension and dollar demand, with foreign investors net buying Rs 407.99 crore and domestic funds net buying Rs 3,973.72 crore. Risk is capped by lingering inflation concerns after July Fed minutes highlighted uneasiness about the need for potentially higher rates; Asian markets were mostly higher (e.g., South Korea’s Kospi +6%), but oil and rate sensitivity keep sentiment mixed.

Analysis

The cleanest read-through is that India is being pulled between an external input shock and a temporary global liquidity bid. If Brent holds in the low-90s, the earnings reset will show up first in fuel-intensive franchises and import-dependent consumers, then in FY26 margin revisions and weaker multiples; the market can rally on macro relief, but it likely won’t sustain if crude keeps outrunning the rupee. The second-order winner is upstream energy exposure, while the second-order loser is anything whose cost base is USD-linked but whose pricing power is local.

The U.S. Treasury buyback is supportive for duration, but only as a term-premium suppressant, not a policy pivot. That means the move should help long-duration assets and gold for days to a few weeks, but the Fed minutes are a reminder that the inflation overhang still caps the upside and makes any rally vulnerable to a quick reversal if supply/demand at the long end normalizes. In other words, buy the squeeze, don’t underwrite a regime change.

SK Hynix’s capital return signal is more interesting than the index pop: it pressures the memory complex to prove that cash generation is structural, not just late-cycle. If DRAM pricing stays firm, this can support Korean semi valuations and force rival capital-allocation discipline; if pricing rolls over, the buyback becomes a peak-cycle tell rather than a catalyst. Moderna’s oncology readout is a positive sentiment event, but the market is likely to overprice platform optionality unless management can translate it into a credible commercial path.

The contrarian risk is that investors are treating three different things as one trade: liquidity support, geopolitical oil risk, and idiosyncratic biotech/semis news. Those have different half-lives, and the most durable one right now is the oil/FX hit to India, not the tactical relief from Treasury operations.

Key Decisions for Investors

• Short INDA or buy INDA puts on strength for a 1-3 month horizon; thesis breaks if Brent falls back below ~$88 or USD/INR retraces decisively under 95.
• Long TLT tactically for 1-3 weeks as a term-premium squeeze trade; fade if the 10Y yield reclaims recent highs or Treasury buyback details underwhelm.
• Long SKHYV vs. short SOXX for 1-3 months as a relative-value expression on capital return discipline in memory; cover if DRAM/NAND pricing softens or AI-driven broad semi momentum overwhelms the pair.
• Do not chase MRNA common after the trial headline; prefer a small call spread only if volume confirms and management updates the commercial path, otherwise treat it as a sentiment pop rather than a durable rerating.
• Watch Indian airlines/consumer importers as the first losers from sustained Brent >$90 and a weaker rupee; if INR trades through 96.5, expect broader Nifty EPS cuts and consider adding to the short basket.